Evidence map›Paper›PMID 33474816›Full record

Observational studyEuropean journal of neurology2021

Neurological complications of COVID-19 in hospitalized patients: The registry of a neurology department in the first wave of the pandemic.

Sofía Portela-Sánchez, Antonio Sánchez-Soblechero, Pedro José Melgarejo Otalora, Ángela Rodríguez López, Gabriel Velilla Alonso, Michael Armando Palacios-Mendoza, Carlos Cátedra Caramé, Laura Amaya Pascasio, Miguel Mas Serrano, Andreu Massot-Tarrús and 7 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in European journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 3 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  9. The Review of Ophthalmic Symptoms in COVID-19.Clinical ophthalmology (Auckland, N.Z.) · 2024
    Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Late peripheral facial paralysis after COVID-19: a rapid systematic review and two case reports.The journal of venomous animals and toxins including tropical diseases · 2022
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Sofía Portela-SánchezDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID https://orcid.org/0000-0003-3396-4642
Antonio Sánchez-SoblecheroDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID https://orcid.org/0000-0002-7098-8494
Pedro José Melgarejo OtaloraDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Ángela Rodríguez LópezDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Gabriel Velilla AlonsoDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Michael Armando Palacios-MendozaDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID https://orcid.org/0000-0002-9271-3942
Carlos Cátedra CaraméDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Laura Amaya PascasioDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Miguel Mas SerranoDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Andreu Massot-TarrúsDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Beatriz De La Casa-FagesDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID https://orcid.org/0000-0003-0486-3308
Fernando Díaz-OteroDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Irene CatalinaDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Jose Manuel García DomínguezDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Javier Ricardo Pérez-SánchezDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.ORCID https://orcid.org/0000-0001-9292-9471
José Luis Muñoz-BlancoDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Francisco GrandasDepartment of Neurology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Hospital General Universitario Gregorio Marañón · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo describe the spectrum of neurological complications observed in a hospital-based cohort of COVID-19 patients who required a neurological assessment.

methodsWe conducted an observational, monocentric, prospective study of patients with a COVID-19 diagnosis hospitalized during the 3-month period of the first wave of the COVID-19 pandemic in a tertiary hospital in Madrid (Spain). We describe the neurological diagnoses that arose after the onset of COVID-19 symptoms. These diagnoses could be divided into different groups.

resultsOnly 71 (2.6%) of 2750 hospitalized patients suffered at least one neurological complication (77 different neurological diagnoses in total) during the timeframe of the study. The most common diagnoses were neuromuscular disorders (33.7%), cerebrovascular diseases (CVDs) (27.3%), acute encephalopathy (19.4%), seizures (7.8%), and miscellanea (11.6%) comprising hiccups, myoclonic tremor, Horner syndrome and transverse myelitis. CVDs and encephalopathy were common in the early phase of the COVID-19 pandemic compared to neuromuscular disorders, which usually appeared later on (p = 0.005). Cerebrospinal fluid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction was negative in 15/15 samples. The mortality was higher in the CVD group (38.1% vs. 8.9%; p = 0.05).

conclusionsThe prevalence of neurological complications is low in patients hospitalized for COVID-19. Different mechanisms appear to be involved in these complications, and there was no evidence of direct invasion of the nervous system in our cohort. Some of the neurological complications can be classified into early and late neurological complications of COVID-19, as they occurred at different times following the onset of COVID-19 symptoms.

Indexed as

COVID-19Nervous System DiseasesNeurologyCOVID-19 TestingHumansPandemicsProspective StudiesRegistriesSARS-CoV-2COVID-19neurological complicationsSARS-CoV-2

Identifiers

PMID33474816
PMCPMC8013314
OpenAlexW3123555565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.